Increased circulating levels of angiotensin-(1–7) in severely ill COVID-19 patients

• Ana Luiza Valle Martins,
• Filipe Alex da Silva,
• Lucas Bolais-Ramos,
• Gisele Capanema de Oliveira,
• Renata Cunha Ribeiro,
• Danilo Augusto Alves Pereira,
• Filippo Annoni,
• Mirella Monique Lana Diniz,
• Thuanny Granato Fonseca Silva,
• Bruna Zivianni,
• Alexandre Carvalho Cardoso,
• Juliana Carvalho Martins,
• Daisy Motta-Santos,
• Maria José Campagnole-Santos,
• Fabio Silvio Taccone,
• Thiago Verano-Braga,
• Robson Augusto Souza Santos

Affiliations

Ana Luiza Valle Martins

National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) – Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Filipe Alex da Silva

National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) – Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Lucas Bolais-Ramos

National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) – Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Gisele Capanema de Oliveira

National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) – Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Renata Cunha Ribeiro

National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) – Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Danilo Augusto Alves Pereira

National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) – Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Filippo Annoni

Dept of Intensive Care, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium

Mirella Monique Lana Diniz

National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) – Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Thuanny Granato Fonseca Silva

National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) – Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Bruna Zivianni

Fundação Hospitalar do Estado de Minas Gerais – FHEMIG, Belo Horizonte, Brazil

Alexandre Carvalho Cardoso

National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) – Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Juliana Carvalho Martins

Fundação Hospitalar do Estado de Minas Gerais – FHEMIG, Belo Horizonte, Brazil

Daisy Motta-Santos

National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) – Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Maria José Campagnole-Santos

National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) – Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Fabio Silvio Taccone

Dept of Intensive Care, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium

Thiago Verano-Braga

National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) – Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Robson Augusto Souza Santos

National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) – Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil